Chuxian Zhao
Overview
Explore the profile of Chuxian Zhao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang Y, Feng D, Zhu J, Wei D, Zhao C, Liu H, et al.
Front Immunol
. 2024 May;
15:1381308.
PMID: 38745670
Chimeric antigen receptor T cells (CAR T) targeting CD7 for T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) showed promising efficacy and safety in some clinical trials. However, most of them were bridged...
2.
Jiang C, Zhang H, Zhao C, Wang L, Hu X, Pan Z
Blood Sci
. 2023 May;
5(2):125-130.
PMID: 37228773
Rothmund-Thomson syndrome (RTS) is a rare autosomal-recessive disorder with clinical features consisting of rash, poikiloderma, sparse hair, short stature, juvenile cataracts, skeletal abnormalities, and cancer predisposition. Genetic studies involving detection...
3.
Zhang X, Qin Y, Fu Z, Zhang B, Su M, Zhao C, et al.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi
. 2023 Jan;
40(2):242-246.
PMID: 36709950
Objective: To explore the genetic basis for a rare case of acute B-lymphocytic leukemia (B-ALL) with double Philadelphia chromosomes (Ph) and double derivative chromosome 9s [der(9)]. Methods: A patient with...
4.
Jiang Y, Feng D, Wang C, Zhang Y, Zhao C, Li S, et al.
Front Med (Lausanne)
. 2022 Nov;
9:1042501.
PMID: 36405594
Background: Neutropenia and cytokine release syndrome (CRS) are two major toxicities of chimeric antigen receptor (CAR)-T cell therapy. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is an ideal candidate treatment for neutropenia except...
5.
Involvement of miR-125a in resistance to daunorubicin by inhibiting apoptosis in leukemia cell lines
Bai H, Zhou L, Wang C, Xu X, Jiang J, Qin Y, et al.
Tumour Biol
. 2017 Apr;
39(4):1010428317695964.
PMID: 28381182
In this study, we investigated whether miR-125a participated in the resistance of the leukemia cell lines to the chemotherapeutic agent daunorubicin. Higher expression of miR-125a is correlated with lower treatment...
6.
Zhao C, Wang C, Cai Q
Zhonghua Xue Ye Xue Za Zhi
. 2015 Jul;
36(6):534-6.
PMID: 26134025
No abstract available.
7.
Qin Y, Wang X, Zhao C, Wang C, Yang Y
Int J Hematol
. 2015 May;
102(2):170-80.
PMID: 25997869
To assess the effect of JAK2V617F on different thrombotic risks in essential thrombocythemia (ET) patients, we identified eligible studies from several databases including Pubmed, Embase, and Cochrane Central Register of...
8.
Wei D, Zhao C, Zhao M, Wei J, Gao Y, Cai Q, et al.
Zhonghua Xue Ye Xue Za Zhi
. 2014 Sep;
35(9):854-6.
PMID: 25246260
No abstract available.
9.
Qin Y, Wang X, Yang Y, Jiang J, Zhao C, Wang C
Zhonghua Xue Ye Xue Za Zhi
. 2014 Aug;
35(8):774.
PMID: 25152137
No abstract available.
10.
Shao S, Li S, Qin Y, Wang X, Yang Y, Bai H, et al.
Int J Oncol
. 2014 Mar;
44(5):1661-8.
PMID: 24585095
Imatinib mesylate (IM), a targeted competitive inhibitor of the BCR-ABL tyrosine kinase, has revolutionized the clinical treatment of chronic myeloid leukemia (CML). However, resistance and intolerance are still a challenge...